Limited Corporate Presentation. February 2009. Glythera Highlights. Glythera’s Patented Permalink ™ technology allows the stable linkage of PEG or Glycan groups to proteins or peptides in vitro , while Permacarb ™ technology renders carbohydrates resistant to enzymatic degradation
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
with a leading European biotechnology
Dr Anthony Baxter- Chairman
Dr Baxter was formerly the founding CEO of Argenta Discovery Ltd, a leading drug discovery services. In less than four years from the company's start-up in 1999, he grew services revenue to over £9 million which included building a pipeline of novel therapeutic programmes. Prior to this, Dr Baxter was Chief Scientific Officer of Oxford Asymmetry International plc and helped build the business from an early stage company to its flotation on the LSE and then to its eventual merger with Evotec for £316 million. Most recently, Dr Baxter lead the turnaround of deltaDOT Ltd, which involved fundraising of £8.3 million. He is currently a Non-Exec. Chairman of Equinox Ltd., and the CEO of Cyprotex Plc, which has recently announced better than expected profits to Shareholders.
Dr Andrew G Watts– Founder and Executive Director
Andrew is currently a Lecturer in Medicinal Chemistry with over 10 years experience in carbohydrate research, including synthesis, inhibitor design, mechanistic enzymology and development of novel technologies. After completing his PhD in Western Australia, he carried out Post-doctoral research in Vancouver, Canada (UBC) before moving to the UK.
Dr Amanda MacKenzie – Founder and Executive Director
Amanda MacKenzie is a Lecturer in Pharmacology with over 10 years research experience in field of ion channels, immunology and hematology. Her experience include a postdoctoral fellowship position in Glaxo Wellcome and a senior fellowship funded by AstraZeneca mentored by Prof. Alan North. She has authored several high impact research papers and reviews in the field of membrane ion channel signalling and small protein cytokine signalling.
Dr Alison Fielding, MBA - Executive Director
Alison was the Chief Operating Officer of Techtran Group when it was acquired by IP Group in January 2005. Previously, she spent five years at McKinsey & Co where she consulted primarily to the pharmaceutical and health care sectors. Prior to McKinsey, Alison spent four years as a development chemist for Zeneca, performing technical roles in the speciality chemicals and agrochemicals divisions.
Prof. William Baines - Non-Executive Director
William is a scientist and entrepreneur. He has 15 years' experience in creating, valuing and implementing new technology in start-up companies, including Ark Therapeutics and Vectura, and has started 4 companies including Amedis Pharmaceuticals Ltd.. He is author of over 100 articles and
3 books, teaches entrepreneurship and company financing at Cambridge University.
Simon Youlton -Business Development
Simon has a 15 year career in sales and marketing in life science companies and a ten year career in international technology transfer. This has included being a Board Member of several life science companies, being a Management Team Member for the worlds largest cancer charity whilst at the tech transfer and drug development company Cancer Research Technology Ltd, & being a founding member of the CRUK translational funding committee set up to receive and review academic translational awards and review the drug development activities of CRT.
The Glythera Approach
GLYTHERA’s core expertise allows the functionalisation of biological therapeutics to improve properties and efficacy of glycoproteins via the implementation of its PermaLink™ and PermaCarb™ technologies.
PermaLink™ is a biologically stable linker which attaches functional groups such as carbohydrates and PEGs to cysteine residues on proteins and peptides .
PermaCarb™ technology renders carbohydrates resistant to enzymatic degradation, maximising their biological effects in vivo.
Our modular approach enables the stable attachment of PermaCarb™s using PermaLink™ to create drugs with improved plasma half-life, biological stability and therapeutic efficacy.
Problems which can be addressed:
Biologics and Biosimilars
Chemistry modulates reactivity
Flexibility and Control
Synthesis of the carbohydrate prior to conjugation assures homogeneity and efficiency.
Unique ability to introduce resistance to enzymatic degradation ensuring maximum benefit from glycosylation is conferred to the therapeutic.
Application of Glythera Technologies
Companies currently using Pegylation
Companies currently using cell-based glycosylation methods
Companies developing peptide-based therapeutics
Partner evaluates Glythera version of peptide/protein cf original form
Partner delivers test peptide or protein
Glythera delivers sample of partner peptide/protein after functionalisation/protection
For further information regarding Glythera Limited,
Glythera Limited, 24 Cornhill, London, EC3V 3ND, Registered Number 6433235